GRCE
Grace Therapeutics, Inc.
$2.30
0.00%
$30.9M
No data for this timeframe.
Vol
Market Cap$30.9M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders4 funds
Inst. Value$3.7M
Inst. Activity2 buys / 0 sells
Reddit Sentiment60° Warm
SEC Reports3
Press Releases1
Recent Activity
Jun 5, 2026
SEC
Grace Therapeutics filed an 8-K announcing the departure of Carrie DAndrea as VP of Clinical Operations effective June 5
8-K — Impact 2/10
Apr 27, 2026
SEC
Grace Therapeutics updated its corporate presentation, disclosing that the FDA issued a Complete Response Letter (CRL) f
8-K — Impact 7/10
Apr 23, 2026
SEC
Grace Therapeutics received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for GTx-104
8-K — Impact 7/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
129,781 shares ($449.0K)
Inst.
MORGAN STANLEY — DOUBLED
25,448 shares ($88.0K)
Apr 23, 2026
other
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
<p align="center"><em>FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemis
Apr 14, 2026
Press
Grace Therapeutics announced that results from its STRIVE-ON Phase 3 safety trial for GTx-104, an IV formulation of nimo
Impact 7/10
Price Targets
$5.89
+152.6% upside
Strong Buy
Current $2.33
Low $3.92
Median $5.89
High $7.85
2 analysts
$3.92
$7.85
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 24, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▲ +16.3% | $-0.20 — $-0.20 | -249% YoY | 1 |
| Next Q | $-0.20 ▲ +11.6% | $-0.20 — $-0.20 | 29% YoY | 1 |
| Current FY | $-1.03 ▲ +11.1% | $-1.30 — $-0.75 | 5% YoY | 2 |
| Next FY | $-0.95 ▼ -7.9% | $-1.09 — $-0.81 | 7% YoY | 2 |
Latest Reports
NEUTRAL
8-K
2/10
Grace Therapeutics filed an 8-K announcing the departure of Carrie DAndrea as VP of Clinical Operations effective June 5
Jun 5, 2026
BEARISH
8-K
7/10
Grace Therapeutics updated its corporate presentation, disclosing that the FDA issued a Complete Response Letter (CRL) f
Apr 27, 2026
BULLISH
Press
7/10
Grace Therapeutics announced that results from its STRIVE-ON Phase 3 safety trial for GTx-104, an IV formulation of nimo
Apr 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BANK OF AMERICA CORP | $1.7M | — |
| VANGUARD GROUP INC | $1.5M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $449.0K | ADD |
| MORGAN STANLEY | $88.0K | DOUBLED |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
4 institutional holders with $3.7M total value (1,073,908 shares) as of 2025-Q4. Top holders: BANK, VANGUARD, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 494,698 | $1.7M | 45.9% | — |
| 2 | VANGUARD GROUP INC | 423,981 | $1.5M | 39.7% | ADD +60.2% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 129,781 | $449.0K | 12.0% | ADD +53.5% |
| 4 | MORGAN STANLEY | 25,448 | $88.0K | 2.4% | DOUBLED +1277.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 84,561 | 129,781 | +53.5% | $449.0K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 1,848 | 25,448 | +1277.1% | $88.0K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 27,625 | 84,561 | +206.1% | $251.7K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 255,400 | 409,100 | +60.2% | $1.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 42,181 | 27,625 | -34.5% | $82.0K | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 23,664 | 38,403 | +62.3% | $87.6K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 42,975 | — | $160.7K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 23,664 | — | $90.2K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.
NEUTRAL
8-K
2/10
Grace Therapeutics filed an 8-K announcing the departure of Carrie DAndrea as VP of Clinical Operati
Jun 5, 2026
BEARISH
8-K
7/10
Grace Therapeutics updated its corporate presentation, disclosing that the FDA issued a Complete Res
Apr 27, 2026
BEARISH
8-K
7/10
Grace Therapeutics received a Complete Response Letter (CRL) from the FDA for its New Drug Applicati
Apr 23, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.89 mean target
+152.6% upside
Strong Buy (3.00)
$3.92 Low
$7.85 High
| Metric | Value |
|---|---|
| Current Price | $2.33 |
| Target Low | $3.92 |
| Target Mean | $5.89 |
| Target Median | $5.89 |
| Target High | $7.85 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.20 | $-0.20 | $-0.20 | -249.3% | +16.3% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-06-30 |
$-0.20 | $-0.20 | $-0.20 | 29.2% | +11.6% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-03-31 |
$-1.03 | $-1.30 | $-0.75 | 5.4% | +11.1% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-03-31 |
$-0.95 | $-1.09 | $-0.81 | 7.4% | -7.9% | 1↑ 1↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.205 | |
| 7d ago | $-0.245 | +0.040 |
| 30d ago | $-0.245 | +0.040 |
| 60d ago | $-0.245 | +0.040 |
| 90d ago | $-0.491 | +0.286 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 24, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
RCKT FLYING UP 16% TODAY
▲ 1
💬 1
⚡ 0.0
Apr 23, 2026
other
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
<p align="center"><em>FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical
Apr 23, 2026
fda_pdufa
PDUFA: GRCE — GTx-104 in aneurysmal Subarachnoid Hemorrhage (aSAH) — 2026-04-23
FDA target action date 2026-04-23 for GRCE (Grace Therapeutics, Inc.). Drug: GTx-104. Indication: aneurysmal Subarachnoid Hemorrhage (aSAH). FDA estab
Apr 22, 2026
short_volume
Short Volume: GRCE — 62.0% short (0.4M / 0.6M)
Short: 367,328 | Exempt: 39,538 | TRF Vol: 592,278 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
fda
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
<p align="justify">PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company),
Mar 13, 2026
short_interest
FTD: GRCE — 269,245 shares ($1.1M) failed to deliver
Settlement: 20260313, Price: $4.06, FTD Value: $1,093,134.7, GRACE THERAPEUTICS, INC. COMMO